阜阳有哪些好点的皮肤科医院安徽阜阳看皮肤科那家医,阜阳皮肤哪家医院,阜阳哪里治疗痒疹好,阜阳市治疗痤疮大概费用,阜阳正规医院治痘痘价格,阜阳看毛囊炎到哪家医院好,阜阳哪里看皮肤病好些

WASHINGTON, Oct. 13 (Xinhua) -- In a trial that included about 35,000 men, those who were randomized to receive daily supplementation with vitamin E had a significantly increased risk of prostate cancer, according to a study published this week in the Journal of the American Medical Association.The study followed more than 35,533 men 50 or older at 427 sites in the United States, Canada and Puerto Rico. The men were divided into four groups who took daily doses of 400 international units of Vitamin E and 200 micrograms of selenium; Vitamin E and a placebo that looked like selenium; selenium and a placebo that looked like Vitamin E; or two placebos. The recommended daily intake of Vitamin E is about 22.4 international units.The researchers from the Cleveland Clinic found that the rate of prostate cancer detection was greater in all treatment groups when compared with placebo but was statistically significant only in the vitamin E alone group -- a 17 percent increased rate of prostate cancer detection. The difference in rates of prostate cancer between vitamin E and placebo became apparent during the participants' third year in the trial. The elevated risk estimate for vitamin E was consistent across both low- and high-grade disease."The observed 17 percent increase in prostate cancer incidence demonstrates the potential for seemingly innocuous yet biologically active substances such as vitamins to cause harm. The lack of benefit from dietary supplementation with vitamin E or other agents with respect to preventing common health conditions and cancers or improving overall survival, and their potential harm, underscore the need for consumers to be skeptical of health claims for unregulated over-the-counter products in the absence of strong evidence of benefit demonstrated in clinical trials," the researchers said.

WASHINGTON, Dec. 12 (Xinhua) -- British scientists have discovered a new way to target cancer through manipulating a master switch responsible for cancer cell growth. The findings, published Monday in the U.S. journal Cancer Cell, reveal how cancer cells grow faster by producing their own blood vessels.Cancer cells gain the nutrients they need by producing proteins that make blood vessels grow, helping deliver oxygen and sugars to the tumor. These proteins are vascular growth factors like VEGF -- the target for the anti-cancer drug Avastin. Making these proteins requires the slotting together of different parts of genes, a process called splicing.Scientists at the University of West England and the University of Bristol discovered that mutations in one specific cancer gene can control how splicing is balanced, allowing a master switch in the cell to be turned on. This master switch of splicing makes cancer cells grow faster, and blood vessels to grow more quickly, as they alter how VEGFs are put together.In experimental models, the researchers found that by using new drugs that block this master switch they prevented blood vessel growth and stopped the growth of cancers."The research clearly demonstrates that it may be possible to block tumor growth by targeting and manipulating alternative splicing in patients, adding to the increasingly wide armory of potential anti-cancer therapies," the authors said.

ZHENGZHOU, Oct. 21 (Xinhua) -- A leading Chinese producer for quick-frozen snacks Thursday apologized for the production and sale of bacteria-contaminated dumplings and said that a recall was underway.A spokeswoman from Zhengzhou Sinian Food Co., Ltd. said they had confirmed the contamination of staphylococcus aureus, or golden staph, in its quick-frozen seafood and pork-stuffed dumplings.The company had started the recall and destruction of the contaminated products, said Lin Xiaohong, a marketing executive of the company, adding that an investigation into the source of the contamination was underway.The statement came after authorities in Beijing announced they had detected golden staph from one batch of dumpling products by the Henan-based company. The bacteria can cause various diseases, including pneumonia and sepsis, and is strictly banned in food procession.

LOS ANGELES, Oct. 3 (Xinhua) -- An organizer of the World Stem Cell Summit says one of the key problems medical researchers face these days is how to apply their findings in the real world."How do you take the phenomenal scientific research going on in labs and translate it into medical treatments,?" said Bernie Siegel, the founder and co-chair of the summit and executive director of the Genetic Policy Institute, which organized the event."It's a big job to do this, and more than just the science," Siegel said, noting that in a growing field now moving beyond basic lab research, the aim is to connect the people who do the work with those who finance it.The three-day summit, which opened Monday in Pasadena, features more than 150 top international speakers and 50 hours of programming with leaders from science, pharmaceutics, business, policy, ethics, law and other fields.The cell therapy industry, a "nascent" field, has emerged to be a potentially multi-billion business with unlimited potential, Siegel said.Stephen Dalton, a University of Georgia professor, reported that one of the biggest developments in stem cell research in the past year was the realization that cells can be transdifferentiated from one state to another without returning to a pluripotent state.Dalton said the principle was previously supported by a few isolated examples but it was not until 2010 that the idea was widely accepted.Mark Sussman, a professor from San Diego State University, called the identification of lung stem cells from human tissue samples capable of regenerating the highly complex and specialized structures of mature lungs a breakthrough in lung biology and regenerative medicine.He said results presented by the Anversa group in the New England Journal of Medicine demonstrate that human lung stem cells can be expanded in vitro and also retain the capacity to integrate into adult tissue upon introduction into mice.The study, Sussman said, has opened up an entirely new field of possibilities for lung regeneration and potential therapeutic applications for many conditions where treatment options are either very limited or nonexistent.

BEIJING, Dec. 14 (Xinhua) -- The People's Bank of China, the country's central bank, said Wednesday that China will continue its prudent monetary policy next year while making the policy more targeted, flexible and forward-looking.The announcement came after the conclusion of the annual central economic work conference Wednesday morning, which has set economic policy guidelines for the coming year.The central bank will maintain control over the intensity, pace and focus of macroeconomic regulation, make full use of monetary tools, tune up credit supply and promote reasonable growth in social financing, according to a statement posted on its website.The bank will improve credit structure, increase support to key sectors and weak areas, especially to agriculture, small and medium-sized enterprises and affordable housing construction, as well as better serve the real economy.It will continue to perfect its yuan exchange rate formation mechanism, and keep the yuan exchange rates basically stable at a reasonable and balanced level.Meanwhile, the bank will strengthen and improve its foreign exchange management, deepen financial system reforms, prevent and solve financial risks, the statement said.